ResMed (RMD) financial statements

+514.0%since 2009
FY2026 revenue
$5.7B▲ +9.9%
FY2026 net income
$1.5B▲ +8.8%
FY2026 diluted EPS
$10.43▲ +9.7%
FY2026 free cash flow
$1.6B▼ −0.7%

ResMed income statement

ResMed income statement
USD millionsFY2026FY2025FY2024
Period ended30 Jun 202630 Jun 202530 Jun 2024
Revenue5,6535,1464,685
Gross profit3,4523,0552,655
Operating income1,8871,6851,320
Pretax income1,9191,6781,265
Net income1,5231,4011,021
Diluted earnings per share10.439.516.92

ResMed balance sheet

ResMed balance sheet
USD millionsFY2026FY2025FY2024
Period ended30 Jun 202630 Jun 202530 Jun 2024
Cash and cash equivalents1,4691,209238
Total assets8,9668,1746,872
Total liabilities2,3812,2072,008
Total equity6,5855,9684,864

ResMed cash flow statement

ResMed cash flow statement
USD millionsFY2026FY2025FY2024
Period ended30 Jun 202630 Jun 202530 Jun 2024
Operating cash flow1,8061,7521,401
Capital expenditure-156-90-99
Free cash flow (derived)1,6501,6621,302
Dividends paid-350-311-282
Share repurchases-700-300-150

Quarterly highlights

Quarterly highlights
USD millionsQ1 FY2027Q4 FY2026Q3 FY2026Q2 FY2026
Period ended30 Sep 202630 Jun 202631 Mar 202631 Dec 2025
Revenue (derived)1,4151,4641,4311,423
Operating income (derived)453449500492
Net income (derived)418383399393
Diluted earnings per share2.92n/a2.742.68
Operating cash flow (derived)422455554340
Total assets8,2128,9668,7848,503

ResMed major shareholders

ResMed major shareholders
HolderShare of classSharesFiled
Vanguard Capital Management8.2%11,961,70629 April 2026
AustralianSuper Pty Ltd5.7%8,276,3817 August 2026
Vanguard Portfolio Management5.4%7,886,48929 April 2026

ResMed 10-K and SEC filings

ResMed 10-K and SEC filings
FiledFormTypeDescription
29 October 202610-QQuarterly reportQuarterly report
29 October 20268-KCurrent reportCurrent report
1 September 20268-KCurrent reportCurrent report
17 August 20268-KCurrent reportCurrent report
13 August 202610-KAnnual reportAnnual report
6 August 20268-KCurrent reportCurrent report
7 July 20268-KCurrent reportCurrent report
30 April 202610-QQuarterly reportQuarterly report

Common questions

What was ResMed's revenue in fiscal 2026?

ResMed reported $5.7 billion in revenue for fiscal 2026, the year ended 30 June 2026, up 9.9% from fiscal 2025.

What was ResMed's net income in fiscal 2026?

ResMed reported net income of $1.5 billion for fiscal 2026, the year ended 30 June 2026, up 8.8% from fiscal 2025. Diluted earnings per share were $10.43.

What was ResMed's free cash flow in fiscal 2026?

ResMed had $1.6 billion in free cash flow in fiscal 2026. Operating cash flow was $1.8 billion and capital expenditure was $156 million.

What were ResMed's total assets at the end of fiscal 2026?

ResMed reported total assets of $9.0 billion at the end of fiscal 2026, the year ended 30 June 2026.

How much ResMed history do I get?

Every account gets the full history, annual and quarterly, with first reported values and as of dates.